Region 11 MELD Na exception prospective study

Robert A Fisher; Douglas M Heuman; Ann M Harper; Martha K Behnke; Alastair D Smith; Mark W Russo; Steven Zacks; John W McGillicuddy; James Eason; Michael K Porayko; Patrick Northup; Michael R Marvin; Johnathan Hundley; Satheesh Nair

2012, Number 1

Ann Hepatol 2012; 11 (1)

Region 11 MELD Na exception prospective study

Fisher RA, Heuman DM, Harper AM, Behnke MK, mith AD, Russo MW, Zacks S, McGillicuddy JW, Eason J, Porayko MK, Northup P, Marvin MR, Hundley J, Nair S

Full text

How to cite this article

Language: English
References: 26
Page: 62-67
PDF size: 89.25 Kb.

ABSTRACT

Introduction. Hyponatremia complicates cirrhosis and predicts short term mortality, including adverse outcomes before and after liver transplantation. Material and methods. From April 1, 2008, through April 2, 2010, all adult candidates for primary liver transplantation with cirrhosis, listed in Region 11 with hyponatremia, were eligible for sodium (Na) exception. Results. Patients with serum sodium (SNa) less than 130 mg/dL, measured two weeks apart and within 30 days of Model for End Stage Liver Disease (MELD) exception request, were given preapproved Na exception. MELD Na was calculated [MELD + 1.59 (135-SNa/30 days)]. MELD Na was capped at 22, and subject to standard adult recertification schedule. On data end of follow-up, December 28, 2010, 15,285 potential U.S. liver recipients met the inclusion criteria of true MELD between 6 and 22. In Region 11, 1,198 of total eligible liver recipients were listed. Sixty-two (5.2%) patients were eligible for Na exception (MELD Na); 823 patients (68.7%) were listed with standard MELD (SMELD); and 313 patients (26.1%) received HCC MELD exception. Ninety percent of MELD Na patients and 97% of HCC MELD patients were transplanted at end of follow up, compared to 49% of Region 11 standard MELD and 40% of U.S.A. standard MELD (USA MELD) patients (p ‹ 0.001); with comparable dropout rates (6.5, 1.6, 6.9, 9% respectively; p = 0.2). MELD Na, HCC MELD, Region 11 SMELD, and USA MELD post-transplant six-month actual patient survivals were similar (92.9, 92.8, 92.2, and 93.9 %, respectively). Conclusion. The Region 11 MELD Na exception prospective trial improved hyponatremic cirrhotic patient access to transplant equitably, and without compromising transplant efficacy.

REFERENCES

Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-8.
Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-80.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end stage liver disease. Hepatology 2001; 33: 464-70.
Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration in MELD. Gastroenterology 2006; 130: 1652-60.
Koller H, Rosenkranz A. Hyponatremia to be an excellent predictor of outcome in patients with advanced cirrhosis. Liver Transpl 2005; 11: 1001-2.
Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-43.
Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802-10.
Cywinski JB, Mascha E, Miller C, et al. Association between donor-recipient serum sodium differences and orthotopic liver transplant graft function. Liver Transpl 2008; 14: 59-65.
Wong VW, Chim AM, Wong GL, et al. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 2007; 13: 1228-35.
Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007; 13: 1174-80.
Londono MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56: 1283-90.
Selcuk H, Uruc I, Ternel MA, et al. Factors prognostic of survival in patients awaiting liver transplantation for endstage liver disease. Dig Dis Sci 2007; 52: 3217-23.
Young AL, Rajagenashan R, Asthana S, et al. The value of MELD and sodium in assessing potential liver transplant recipients in the United Kingdom. Transpl Int 2007; 20: 331-7.
Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-26.
Freeman RB. MELD and Liver Allocation: Continuous Quality Improvement. Hepatology 2004; 40: 787-9.
Roberts JP, Dykstra DM, Goodrich NP, Rush SH, Merion RM, Port FK. Geographic differences in event rates by Model for End-Stage Liver Disease score. Am J Transplant 2006; 6: 2470-5.
Barshes NR, Becker NS, Washburn WK, Halff GA, Aloia TA, Goss JA. Geographic disparities in deceased donor liver transplantion within a single UNOS region. Liver Transpl 2007; 13: 747-51.
Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant 2005; 5: 2244-7.
Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976; 21: 249-56.
Angeli P, Wong F Watson H, Gines P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44: 1535-42.
Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000; 32: 605-10.
Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
Hackworth WA, Heuman DM, Sanyal AJ, Fisher RA, et al. Effects of hyponatremia on outcomes following orthotopic liver transplantation. Liver International 2009; 29(7): 1071-7.
Yun BC, Kim WR, Benson JT, Biggins SW, Thermeall TM, Kremers WK, Rosen CB, Klintmalm GB. Impact of pretransplant Hyponatremia on outcome following Liver Transplantation. Hepatology 2009; 49: 1610-5.
Som-Souk Ma, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites indentifies patients with low model for end stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transplantation 2011; 17: 129-36.